Every time you choose not to listen to a patient because you want the money, it’s the medical equivalent of logging a forest—you don’t care about the soil erosion and the desertification that will result.
A new oral antifungal (oteseconazole) specifically indicated for the treatment of RVVC was approved
in the United States in April 2022 and is currently on fast-track, priority review by Health Canada.